Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Next-generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B-cell precursor acute lymphoblastic leukaemia.
Bendig S, Bufe S, Kotrova M, Fricke B, Proske C, Darzentas F, Darzentas N, Schilhabel A, Kehden B, Chitadze G, Baldus CD, Gökbuget N, Brüggemann M. Bendig S, et al. Br J Haematol. 2024 Oct 24. doi: 10.1111/bjh.19834. Online ahead of print. Br J Haematol. 2024. PMID: 39449173 No abstract available.
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.
Neumann M, Beder T, Bastian L, Hänzelmann S, Bultmann M, Wolgast N, Hartmann A, Trautmann H, Ortiz-Tanchez J, Schlee C, Schroeder M, Fransecky L, Vosberg S, Fiedler W, Alakel N, Heberling L, Kondakci M, Starck M, Schwartz S, Raffel S, Müller-Tidow C, Schneller F, Reichle A, Burmeister T, Greif PA, Brüggemann M, Gökbuget N, Baldus CD. Neumann M, et al. Leukemia. 2024 Jun;38(6):1213-1222. doi: 10.1038/s41375-024-02264-0. Epub 2024 May 14. Leukemia. 2024. PMID: 38744920 Free PMC article.
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Zhao Y, Laird AD, Roberts KG, Yafawi R, Kantarjian H, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien S, Jabbour E, Cassaday RD, Loyd MR, Olsen S, Neale G, Liu X, Vandendries E, Advani A, Mullighan CG. Zhao Y, et al. Blood Adv. 2024 Jun 25;8(12):3226-3236. doi: 10.1182/bloodadvances.2023012430. Blood Adv. 2024. PMID: 38607410 Free PMC article. Clinical Trial.
Monitoring Measurable Residual Disease in ALL and AML.
Bader P, Kreyenberg H, Ossenkoppele G. Bader P, et al. 2024 Apr 11. In: Sureda A, Corbacioglu S, Greco R, Kröger N, Carreras E, editors. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 57. 2024 Apr 11. In: Sureda A, Corbacioglu S, Greco R, Kröger N, Carreras E, editors. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 57. PMID: 39437092 Free Books & Documents. Review.
In ALL evaluation of molecular treatment response, assessment of minimal residual disease, nowadays named measurable residual disease (MRD), is a substantial independent predictor of outcome, as proven by randomized studies (Conter et al. 2010; Gokbuget et al. 2012; Bassan …
In ALL evaluation of molecular treatment response, assessment of minimal residual disease, nowadays named measurable residual disease (MRD), …
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
Burmeister T, Ströh AS, Kehden B, Trautmann H, Meyer C, Marschalek R, Larghero P, Schwartz S, Steffen B, Spriewald B, Heinicke T, Jäkel N, Westermann J, Nachtkamp K, Viardot A, Topp MS, Neumann M, Baldus CD, Gökbuget N, Brüggemann M. Burmeister T, et al. Leukemia. 2024 Jul;38(7):1600-1603. doi: 10.1038/s41375-024-02209-7. Epub 2024 Mar 22. Leukemia. 2024. PMID: 38519799 Free PMC article. No abstract available.
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults.
Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, Gökbuget N, Hauer J, Müller F, Schlegel PG, Frühwald M, Schmid C, Troeger A, Baldus C, Meisel R, Künkele A, Topp M, Bourquin JP, Cario G, Von Stackelberg A, Peters C. Feuchtinger T, et al. Haematologica. 2024 Dec 1;109(12):3892-3903. doi: 10.3324/haematol.2023.283780. Haematologica. 2024. PMID: 38356450 Free PMC article. Review.
Management of ALL in adults: 2024 ELN recommendations from a European expert panel.
Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann O, Rijneveld A, Rousselot P, Ribera J, Bassan R. Gökbuget N, et al. Blood. 2024 May 9;143(19):1903-1930. doi: 10.1182/blood.2023023568. Blood. 2024. PMID: 38306595 Review.
235 results